Up next

Autoplay

Fosamax post approval label changes - protecting the patient or the pharmaceutical company?

0 Views • 08/19/25
Share
Side Effects
Side Effects
Subscribers
0

Suzzane Robotti founder and CEO of MedShadow discusses the FDA drug approval process with emphasis on the risks and complications of the osteoporosis treatment drug Fosamax. Health Watch USA(sm) Patient Safety Conference Oct. 17, 2019.

Show more
0 Comments sort Sort By

Up next

Autoplay